NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Orbimed Advisors Llc sold 1,781 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $14.06, for a total value of $25,040.86. Following the completion of the transaction, the insider now owns 3,435,541 shares in the company, valued at approximately $48,303,706.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, April 22nd, Orbimed Advisors Llc sold 24,609 shares of NeuroPace stock. The shares were sold at an average price of $14.05, for a total value of $345,756.45.
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The shares were sold at an average price of $14.06, for a total value of $36,879.38.
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The shares were sold at an average price of $14.01, for a total value of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51.
NeuroPace Trading Up 3.1 %
NPCE opened at $13.39 on Friday. NeuroPace, Inc. has a 1-year low of $3.80 and a 1-year high of $18.15. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. The stock’s 50 day simple moving average is $14.25 and its 200 day simple moving average is $11.59.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Kent Lake Capital LLC lifted its stake in shares of NeuroPace by 16.8% during the 4th quarter. Kent Lake Capital LLC now owns 670,946 shares of the company’s stock worth $6,917,000 after purchasing an additional 96,529 shares during the period. Citigroup Inc. purchased a new position in shares of NeuroPace during the 3rd quarter worth $29,000. EAM Investors LLC purchased a new position in shares of NeuroPace during the 3rd quarter worth $1,378,000. Finally, Barclays PLC lifted its stake in shares of NeuroPace by 9,085.6% during the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock worth $105,000 after purchasing an additional 10,721 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.
Analyst Ratings Changes
Several research firms have issued reports on NPCE. Cantor Fitzgerald boosted their target price on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Wells Fargo & Company upgraded NeuroPace from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. Leerink Partnrs reiterated an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th. Morgan Stanley boosted their target price on NeuroPace from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 6th. Finally, SVB Leerink began coverage on NeuroPace in a research report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.67.
View Our Latest Report on NPCE
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
- Five stocks we like better than NeuroPace
- What is a SEC Filing?
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks Leading the U.S. Agriculture Comeback
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.